Disproportionality analyses of acoltremon: a real-world safety assessment based on the the FDA adverse event reporting system database
{{output}}
Introduction: Acoltremon is a first-in-class transient receptor potential melastatin 8 agonist approved for the treatment of the signs and symptoms of dry eye disease. Given its increasing clinical use following recent approval, ... ...
